Kaléo Pharma is a pharmaceutical company based in Richmond, Virginia. It was founded by twin brothers who suffered from serious allergies, and were forced to carry a dose of epinephrine with them at all times, which led them to create a new way to administer this dose and establish a whole new method of injection.
The company prides itself in being a “new kind of pharmaceutical company” with the intent of saving people from life threatening medical conditions. According to their website, they believe that the most knowledgeable person about how a disease effects a patient is the patient themselves. The company insists that it is patient oriented, a very smart business strategy, as our business world continues to move more and more customer centered.
The company’s mission is to “provide demonstrably superior medical products that empower you and your caregivers to confidently take control in potentially life threatening situations.” Throughout the Kaléo website, they stress patient and customer oriented treatment, as well as their deep catalog of knowledge on various medical conditions. Every product they release is a combination of a proven medicine and a new, innovative way to administer the medicine. This is meant to keep the company ahead of the rest of the industry, as well as create and discover convenient and efficient ways for the patient to get their treatment.
Along with their Mission Statement, Kaléo displays six company values, titled “The Kaléo Way”. The six steps are: Purposeful/Passionate Culture, Personal Integrity, Mutual Respect, Professional Accountability, Winning Teamwork, and Innovation/Excellence.
Some of the products that they produce are Evzio, a naloxone HCL injection used to treat depression and opioid overdoses, and Auvi-Q, a product in direct competition with the epi-pen and the cause of much controversy in regards to its affordability.
The corporate history of Kaléo, founded 2008, actually began as the corporate history of Intelliject, Inc.- the original name of the company before the switch was made in January of 2014. The reason for the name change is because the name itself is meant to align with the company’s vision and mission, as “kaléo” is derived from the Greek word for “purpose”, as the company has always stressed that their mission and goals are patient oriented.
Kaléo is a private company, therefore there is no stock information available. That being said, the pharmaceutical industry rakes in over $1 Trillion worldwide, with the North American market accounting for nearly 49%, or just under $500 Million, of the worldwide revenue. Kaléo is competitive with all of its products, so it is safe to say that they do make money- the exact amount is just difficult to say from an outside position.